MXCT

MaxCyte Inc

MXCT, USA

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

https://www.maxcyte.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
MXCT
stock
MXCT

Fed Watch: What analyst consensus says on IACVV stock - CPI Data & Daily Market Momentum Tracking moha.gov.vn

Read more →
MXCT
stock
MXCT

Cellares (MXCT) hires former MaxCyte commercial chief as CCO to steer IDMO rollout and IPO preparation Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$6.68

Analyst Picks

Strong Buy

6

Buy

0

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.93

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-6.89 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-5.82 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-113.60 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.18

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 83.16% of the total shares of MaxCyte Inc

1.

BlackRock Inc

(9.57%)

since

2025/06/30

2.

Cadian Capital Management LP

(8.362%)

since

2025/06/30

3.

Morgan Stanley - Brokerage Accounts

(6.5901%)

since

2025/06/30

4.

Mirabella Financial Services LLP

(6.191%)

since

2025/06/30

5.

Vanguard Group Inc

(5.2545%)

since

2025/06/30

6.

Vitruvian Partners

(4.7308%)

since

2025/06/30

7.

Mudita Advisors LLP

(3.1618%)

since

2025/06/30

8.

RGI UK Listed Smaller Coms B Acc

(3.0955%)

since

2025/07/31

9.

Vanguard Total Stock Mkt Idx Inv

(2.5803%)

since

2025/07/31

10.

Unicorn AIM VCT Ord

(2.3315%)

since

2025/08/31

11.

Geode Capital Management, LLC

(2.3268%)

since

2025/06/30

12.

iShares Russell 2000 ETF

(2.3103%)

since

2025/08/31

13.

AXA SA

(2.0659%)

since

2025/06/30

14.

AXA Framlington Health Fund - R Income

(2.0659%)

since

2025/07/31

15.

State Street Corp

(2.0476%)

since

2025/06/30

16.

FMR Inc

(1.8153%)

since

2025/06/30

17.

Dimensional Fund Advisors, Inc.

(1.6366%)

since

2025/06/30

18.

Chevy Chase Trust Holdings, Inc.

(1.6164%)

since

2025/06/30

19.

IFSL Marlborough UK Micro Cap Gr A Acc

(1.1397%)

since

2025/05/31

20.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0966%)

since

2025/07/31

21.

Silvercrest Asset Management Group LLC

(1.008%)

since

2025/06/30

22.

Citadel Advisors Llc

(0.9644%)

since

2025/06/30

23.

Fidelity Small Cap Index

(0.964%)

since

2025/06/30

24.

iShares Russell 2000 Value ETF

(0.8554%)

since

2025/08/31

25.

River UK Micro Cap Ord

(0.7824%)

since

2025/06/30

26.

Northern Trust Corp

(0.7371%)

since

2025/06/30

27.

Fidelity Advisor Equity Growth I

(0.711%)

since

2025/07/31

28.

Morgan Stanley Inst Inception I

(0.691%)

since

2025/06/30

29.

Morgan Stanley Inception

(0.691%)

since

2025/06/30

30.

Renaissance Technologies Corp

(0.6733%)

since

2025/06/30

31.

MI Chelverton UK Equity Growth B Acc

(0.6566%)

since

2025/08/31

32.

Royce & Associates, LP

(0.6164%)

since

2025/06/30

33.

Fidelity VIP Growth Initial

(0.6%)

since

2025/07/31

34.

iShares Biotechnology ETF

(0.5426%)

since

2025/08/31

35.

Fidelity Extended Market Index

(0.5373%)

since

2025/07/31

36.

Royce Micro Cap Trust

(0.4506%)

since

2025/06/30

37.

Vanguard Russell 2000 ETF

(0.4471%)

since

2025/07/31

38.

EQ/Morgan Stanley Small Cap Growth K

(0.4396%)

since

2025/07/31

39.

Goldman Sachs Group Inc

(0.4152%)

since

2025/06/30

40.

Rice Hall James & Associates, LLC

(0.392%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.1

Latest Release

Date

2025-09-30

EPS Actual

-0.12

EPS Estimate

-0.1133

EPS Difference

-0.0067

Surprise Percent

-5.9135%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.